Short Interest Update on Curis (CRIS)

Curis (CRIS) has 4,149,758 shares of shorts outstanding as on August 15, 2016, with 18 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 4,168,699 shares. The stock has a decent trading volume of 226,880 shares daily. The marginal decrease in the short positions is by -0.5%, which amounts to -18,941 shares. Short positions are 3.8% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.

Curis (NASDAQ:CRIS): The stock opened at $1.80 on Wednesday but the bulls could not build on the opening and the stock topped out at $1.92 for the day. The stock traded down to $1.63 during the day, due to lack of any buying support eventually closed down at $1.67 with a loss of -6.70% for the day. The stock had closed at $1.79 on the previous day. The total traded volume was 670,498 shares.


In a related news, The Securities and Exchange Commission has divulged that Greenacre Martyn D, director of Curis Inc, had unloaded 15,000 shares at an average price of $1.69 in a transaction dated on May 27, 2016. The total value of the transaction was worth $25,350.

Curis, Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Companys drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis product pipeline also includes CUDC-427, an orally available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma, and human epidermal growth factor receptor 2 (HER 2-), estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Companys PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.